OncoHost's PROphetNSCLC® Data Presentation at WCLC 2026 Highlights Predictive Accuracy Beyond Initial Sampling

OncoHost's PROphetNSCLC® Presentation at WCLC 2026

OncoHost has made waves in the world of precision oncology, especially with its upcoming presentation at the 2026 World Conference on Lung Cancer (WCLC) from September 12 to 15 in Seoul, South Korea. The company will unveil critical findings related to its PROphetNSCLC® biomarker test, which aims to enhance treatment decision-making for patients with advanced non-small cell lung cancer (NSCLC).

Understanding PROphetNSCLC®

PROphetNSCLC® is a sophisticated plasma proteomics-based assay developed to guide immune checkpoint inhibitor (ICI) treatment. Initial studies established its predictive performance using pre-treatment samples collected from patients. However, clinical realities sometimes necessitate starting treatment before obtaining these baseline blood samples. This adaptability could meaningfully broaden the biomarker’s real-world utility.

The study titled "PROphetNSCLC Maintains Predictive Performance in Longitudinal Sampling Beyond Baseline in Metastatic NSCLC" explores whether the PROphetNSCLC® results remain reliable even if blood samples are drawn after patients begin chemotherapy or immunotherapy. The motivation behind this research stems from the understanding that while the assay is effective at the onset, its applicability during ongoing treatment cycles has not been fully examined.

Study Insights

Led by notable figures in the oncology field such as Dr. David Gandara and Dr. Fred Hirsch, the study involved an analysis of plasma samples from patients undergoing various treatment stages. These patients were not limited to pre-treatment samples but included those who commenced therapy, providing a more comprehensive understanding of the biomarker's predictive capabilities.

Key results from the study reflected that the signals from the PROphet assay remained remarkably consistent even after patients initiated their treatment regimens. In comparing samples collected from patients at baseline to those acquired after chemotherapy and ICI cycles, only 20 of the 7,289 proteins tested showed differential expression, with no changes noted in the critical Resistance Associated Proteins (RAPs) used by PROphet®.

This remarkable preservation of the biological signal signifies that the tool's predictive performance did not falter under treatment-induced changes, demonstrating strong correlations between matched samples. In cases where ICI based treatment was administered, while greater proteomic shifts were noted, a staggering 73% of RAPs still demonstrated strong correlations between the corresponding samples.

Significance of Findings

The implications of this research are vast. As immunotherapy remains a cornerstone in treating NSCLC, the data reinforces the reliability of PROphetNSCLC® in guiding treatment decisions for patients who may not have baseline samples readily available. Such advancements update the clinical narrative, showcasing how this biomarker can reliably predict patient benefits from immunotherapy even post-treatment initiation, thereby enhancing its clinical relevance.

"These findings represent an important step in expanding the real-world clinical utility of PROphetNSCLC®," stated Ofer Sharon, CEO of OncoHost. This perspective aligns closely with the evolving needs of patients and oncologists within the clinical environment, legitimizing the assay's use beyond traditional sample ranges. The assertion is clear: OncoHost is committed to facilitating precision oncology practices that are adaptive and informed by robust data.

Final Thoughts

As OncoHost prepares for its presentation at WCLC 2026, the revelations surrounding PROphetNSCLC® offer promising insights into the future of NSCLC treatment. The ability to adapt predictive biomarkers to real-world clinical settings significantly enhances treatment personalization and ensures that patients receive tailored healthcare, even when standard practices dictate otherwise.

This journey towards refining and expanding the applicability of proteomics in oncology is crucial for fostering a future where patients benefit from targeted therapies throughout their treatment pathways. The upcoming poster presentation will undoubtedly be a highlight of the conference, offering hope for patients navigating the complexities of advanced non-small cell lung cancer.